In the face of mounting criticism over insulin prices, Novo Nordisk (NVO) is mimicking its rivals by launching two programs that are designed to mitigate rising costs for patients.
The two-pronged effort involves a $99 cash card that can be used by anyone — regardless of whether they have insurance coverage — for a month’s supply and the introduction of authorized generic versions of two different insulin products at half the list price. These will be identical to the Novolog and Novolog Mix brand-name treatments and will be made at the same facility, but will carry modified labeling.
Continue to STAT Plus to read the full story…
Anupam Ghose, a physician by training, was diagnosed with Type 2 Diabetes Mellitus (T2DM) in 2017. After the diagnosis of T2DM, he followed a low carbohydrate high fat diet and reversed his T2DM within a year. Now he has one main goal in life. Yes, it is to make people understand that the conventional method of treating T2DM is not beneficial. The best way to reverse and fight T2DM is through diet and lifestyle modification. He decided to help people suffering from T2DM in their new journey by offering consultations and working together with them in order to achieve a T2DM free life.
